Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy

Milinkovic A(2004)Nevirapine in the treatment of HIV Expert Rev Anti-Infect Ther 2 367-373

Martínez E(2016)Dat’AIDS study group. Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide cohort study Medicine (Baltimore) 95 110-117

De Boissieu P(2010)Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients HIV Clin Trials 11 120-125

Dramé M(2015)Effectiveness of a treatment switch to Nevirapine plus Tenofovir and Emtricitabine (or lamivudine) in adults with HIV-1 suppressed viremia PLoS One 10 S21-S33

Raffi F(2004)Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals J Acquir Immune Defic Syndr 35 S80-S89

Reliquet V(2003)A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients J Acquir Immune Defic Syndr 34 1689-1699

Allavena C(2004)Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors Clin Infect Dis 38 325-333

Morineau-Le Houssine P(2017)Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan PLoS One 12 448-452

Mounoury O(2009)Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy AIDS 23 825-829

Raffi F(2007)EuroSIDA study group. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naïve and -experienced HIV-infected patients with high and low CD4+ T-cell counts Antivir Ther 12 895-901

Milinkovic A(2004)Nevirapine in the treatment of HIV Expert Rev Anti-Infect Ther 2 367-373

Martínez E(2016)Dat’AIDS study group. Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide cohort study Medicine (Baltimore) 95 110-117

De Boissieu P(2010)Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients HIV Clin Trials 11 120-125

Dramé M(2015)Effectiveness of a treatment switch to Nevirapine plus Tenofovir and Emtricitabine (or lamivudine) in adults with HIV-1 suppressed viremia PLoS One 10 S21-S33

Raffi F(2004)Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals J Acquir Immune Defic Syndr 35 S80-S89

Reliquet V(2003)A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients J Acquir Immune Defic Syndr 34 1689-1699

Allavena C(2004)Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors Clin Infect Dis 38 325-333

Morineau-Le Houssine P(2017)Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan PLoS One 12 448-452

Mounoury O(2009)Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy AIDS 23 825-829

Raffi F(2007)EuroSIDA study group. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naïve and -experienced HIV-infected patients with high and low CD4+ T-cell counts Antivir Ther 12 895-901